Rye Brook Capital LLC Takes Position in Astera Labs, Inc. $ALAB

Key Points

• Rye Brook Capital LLC has acquired a new stake in Astera Labs, purchasing 9,100 shares valued at approximately $823,000, making it the 17th largest holding in its portfolio.
• Insider selling has been notable, with CEO Jitendra Mohan and Director Manuel Alba selling significant shares, which included 1,308,772 shares worth $214 million in the last quarter.
• Analysts have mixed views on Astera Labs, with a consensus rating of "Moderate Buy" and an average price target of $159.83, reflecting the varying outlook on the stock's performance.

Rye Brook Capital LLC bought a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 9,100 shares of the company's stock, valued at approximately $823,000. Astera Labs comprises 0.9% of Rye Brook Capital LLC's investment portfolio, making the stock its 17th largest holding.

Several other hedge funds have also modified their holdings of the stock. Maryland State Retirement & Pension System lifted its holdings in shares of Astera Labs by 37.7% during the second quarter. Maryland State Retirement & Pension System now owns 6,960 shares of the company's stock valued at $629,000 after purchasing an additional 1,906 shares during the last quarter. Virtus Wealth Solutions LLC raised its position in Astera Labs by 81.6% during the second quarter. Virtus Wealth Solutions LLC now owns 81,165 shares of the company's stock valued at $7,339,000 after buying an additional 36,465 shares during the period. Venturi Wealth Management LLC acquired a new position in Astera Labs during the second quarter valued at $289,000. Friedenthal Financial acquired a new position in Astera Labs during the second quarter valued at $1,018,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Astera Labs during the second quarter valued at $2,514,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Jitendra Mohan sold 152,517 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $170.33, for a total transaction of $25,978,220.61. Following the transaction, the chief executive officer owned 450,001 shares of the company's stock, valued at approximately $76,648,670.33. This represents a 25.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Manuel Alba sold 183,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $173.27, for a total value of $31,708,410.00. Following the transaction, the director directly owned 385,863 shares in the company, valued at approximately $66,858,482.01. This represents a 32.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,308,772 shares of company stock worth $214,482,678. Insiders own 12.50% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ALAB shares. Stifel Nicolaus set a $145.00 price target on Astera Labs and gave the company a "buy" rating in a research report on Monday, August 4th. Bank of America started coverage on Astera Labs in a research report on Friday, October 3rd. They set a "neutral" rating and a $230.00 price target on the stock. CICC Research started coverage on Astera Labs in a research report on Friday, August 29th. They set an "outperform" rating and a $190.00 price target on the stock. Zacks Research lowered Astera Labs from a "strong-buy" rating to a "hold" rating in a research report on Monday. Finally, TD Cowen started coverage on Astera Labs in a research report on Wednesday, October 1st. They set a "hold" rating and a $200.00 price target on the stock. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $159.83.

Astera Labs Price Performance

Shares of ALAB stock opened at $219.36 on Thursday. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The stock's 50-day moving average is $195.44 and its two-hundred day moving average is $122.20. The firm has a market cap of $36.46 billion, a P/E ratio of 391.71, a PEG ratio of 5.28 and a beta of 1.43.

Astera Labs (NASDAQ:ALAB - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.11. The company had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The business's revenue was up 149.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.